Emily Sarah Charlson, MD
Ophthalmology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
Offices
1 location · Pacific Eye Associates, A Medical Corporation · 12 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Ctr-Davies Campus Hosp. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Charlson’s office at (415) 923-3007 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A137508 · Current
Licensed to practise in California · since 2015 · expires 2027-03-31 · Perelman School of Medicine at the University of Pennsylvania.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$285,226
Medicare paid this office $285,226 for 796 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 601 | $79,314 | $96 |
| Removal of excessive skin and fat of upper eyelid | 47 | $38,503 | $819 |
| Reconstruction of eyelid margin | 71 | $30,236 | $426 |
| New patient visit (45+ min) | 179 | $21,084 | $118 |
| Short return visit (20+ min) | 246 | $20,068 | $70 |
See all 19 services
| Return visit (30+ min) | 601 | $79,314 | $96 |
| Removal of excessive skin and fat of upper eyelid | 47 | $38,503 | $819 |
| Reconstruction of eyelid margin | 71 | $30,236 | $426 |
| New patient visit (45+ min) | 179 | $21,084 | $118 |
| Short return visit (20+ min) | 246 | $20,068 | $70 |
| Removal of up to 1/4 of eyelid margin and repair of eyelid | 36 | $19,508 | $500 |
| Suture repair of turning-inward eyelid defect | 49 | $15,957 | $326 |
| Shortening or advancement of upper eyelid muscle to correct drooping or paralysis | 21 | $15,479 | $737 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | 14 | $7,307 | $522 |
| Imaging of retina | 171 | $5,773 | $32 |
| Exam of visual field with intermediate testing | 116 | $4,603 | $38 |
| Injection into skin growth, 1-7 growths | 77 | $4,288 | $45 |
| Insertion of probe into nasal tear duct | 20 | $2,464 | $117 |
| Removal of chronic growth of eyelid | 18 | $1,750 | $92 |
| Exam of visual field with extended testing | 16 | $944 | $52 |
| Photography of content of eyes | 32 | $704 | $22 |
| Imaging of optic nerve | 21 | $694 | $30 |
| Removal of foreign body from external eye (conjunctiva or sclera) | 15 | $460 | $31 |
| Extended exam of the back part of the eye with retinal drawing | 12 | $235 | $20 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 21 | More than 75% of doctors who do this |
Who their Medicare patients are
796 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 11% · Women 66% · Also on Medicaid 32% · Health risk score 1.02. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 61% · Diabetes 28% · Coronary heart disease 17% · Depression 17% · Chronic kidney disease 14% · Cancer 14% · Atrial fibrillation 13% · Heart failure 9% · COPD 7% · Dementia 6% · Stroke 6%.
The office billed $930,391, Medicare allowed $398,164 and paid $285,226; for 2,285 services of 40 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 796 | 2,285 | 75 | 1.02 | $930,391 | $285,226 |
| 2023 | 797 | 2,147 | 75 | 0.98 | $952,176 | $299,471 |
| 2022 | 895 | 2,681 | 76 | 0.99 | $1,246,862 | $382,962 |
| 2021 | 795 | 2,616 | 75 | 1.10 | $1,393,816 | $410,041 |
| 2020 | 387 | 1,348 | 75 | 1.07 | $508,592 | $155,868 |
| 2019 | 214 | 305 | 73 | 1.50 | $119,252 | $23,306 |
| 2018 | 68 | 83 | 73 | 1.58 | $19,479 | $5,463 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Return visit (30+ min) | 590 | $75,964 | $103 |
| Removal of excessive skin and fat of upper eyelid | 40 | $36,085 | $902 |
| Reconstruction of eyelid margin | 70 | $33,091 | $460 |
| Short return visit (20+ min) | 286 | $27,526 | $72 |
| Shortening or advancement of upper eyelid muscle to correct drooping or paralysis | 24 | $20,529 | $855 |
| Removal of up to 1/4 of eyelid margin and repair of eyelid | 33 | $19,940 | $525 |
| New patient visit (45+ min) | 124 | $14,353 | $116 |
| Suture repair of turning-inward eyelid defect | 32 | $11,584 | $362 |
| Correction of widely-opened upper eyelid | 15 | $6,194 | $413 |
| Imaging of retina | 156 | $5,746 | $35 |
| Exam of visual field with intermediate testing | 122 | $5,032 | $41 |
| Insertion of probe into nasal tear duct | 25 | $3,257 | $130 |
| Injection into skin growth, 1-7 growths | 37 | $2,488 | $52 |
| Removal of chronic growth of eyelid | 13 | $1,591 | $114 |
| Exam of visual field with extended testing | 22 | $1,181 | $54 |
| Imaging of optic nerve | 27 | $888 | $32 |
2022: 23 services
| Return visit (30+ min) | 656 | $92,036 | $105 |
| Reconstruction of eyelid margin | 89 | $43,049 | $478 |
| Removal of excessive skin and fat of upper eyelid | 49 | $40,637 | $829 |
| Short return visit (20+ min) | 369 | $36,685 | $75 |
| Shortening or advancement of upper eyelid muscle to correct drooping or paralysis | 35 | $26,988 | $771 |
| Suture repair of turning-inward eyelid defect | 45 | $16,014 | $356 |
| Removal of up to 1/4 of eyelid margin and repair of eyelid | 28 | $15,576 | $537 |
| New patient visit (45+ min) | 140 | $14,639 | $105 |
| Reconstruction of eyelid margin | 22 | $8,362 | $380 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | 13 | $8,005 | $616 |
| Correction of widely-opened upper eyelid | 18 | $6,922 | $385 |
| Imaging of retina | 159 | $6,196 | $35 |
| Exam of visual field with intermediate testing | 151 | $6,106 | $40 |
| Insertion of probe into nasal tear duct | 40 | $5,909 | $137 |
| Shortening or advancement of upper eyelid muscle to correct drooping or paralysis | 12 | $4,913 | $409 |
| Removal of chronic growth of eyelid | 21 | $2,385 | $114 |
| Exam of visual field with extended testing | 32 | $1,828 | $49 |
| Extended exam of the back part of the eye with retinal drawing | 73 | $1,448 | $19 |
| Imaging of optic nerve | 37 | $1,373 | $32 |
| Injection into skin growth, 1-7 growths | 26 | $1,077 | $40 |
| Removal of foreign body from external eye (conjunctiva or sclera) | 19 | $623 | $33 |
| Photography of content of eyes | 27 | $585 | $22 |
| Photography of the retina | 13 | $441 | $34 |
2021: 30 services
| Established patient complete exam of visual system | 552 | $91,099 | $111 |
| Reconstruction of eyelid margin | 60 | $28,338 | $465 |
| Repair of brow paralysis | 27 | $26,472 | $980 |
| Removal of excessive skin and fat of upper eyelid | 39 | $24,020 | $616 |
| Correction of widely-opened upper eyelid | 29 | $22,618 | $780 |
| Established patient problem focused exam of visual system | 170 | $17,377 | $90 |
| Return visit (30+ min) | 117 | $15,314 | $120 |
| Shortening or advancement of upper eyelid muscle to correct drooping or paralysis | 20 | $15,164 | $758 |
| Reconstruction of eyelid margin | 42 | $14,022 | $334 |
| Removal of excessive skin and fat of upper eyelid | 24 | $13,199 | $550 |
| Correction of widely-opened upper eyelid | 30 | $12,071 | $402 |
| Repair of brow paralysis | 28 | $10,910 | $390 |
| Shortening or advancement of upper eyelid muscle to correct drooping or paralysis | 22 | $9,339 | $425 |
| Short return visit (20+ min) | 99 | $8,875 | $81 |
| Complicated repair of wound of eyelids, nose, ears, or lip, 1.1-2.5 cm | 21 | $8,599 | $391 |
| New patient visit (45+ min) | 72 | $8,297 | $115 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | 13 | $7,533 | $579 |
| Suture repair of turning-inward eyelid defect | 19 | $7,293 | $365 |
| New patient complete exam of visual system | 53 | $6,615 | $125 |
| Exam of visual field with intermediate testing | 143 | $6,582 | $45 |
| Insertion of probe into nasal tear duct | 37 | $6,016 | $147 |
| Imaging of retina | 87 | $3,506 | $39 |
| Removal of chronic growth of eyelid | 29 | $3,383 | $109 |
| Suture repair of turning-inward eyelid defect | 11 | $2,521 | $229 |
| Extended exam of the back part of the eye with retinal drawing | 95 | $2,342 | $23 |
| Exam of visual field with extended testing | 23 | $2,025 | $61 |
| Imaging of optic nerve | 29 | $1,084 | $34 |
| Removal of foreign body from external eye (conjunctiva or sclera) | 24 | $936 | $35 |
| Injection into skin growth, 1-7 growths | 16 | $626 | $37 |
| Removal of eyelashes using forceps | 15 | $392 | $16 |
2020: 18 services
| Established patient complete exam of visual system | 248 | $47,963 | $123 |
| Removal of excessive skin and fat of upper eyelid | 19 | $14,558 | $766 |
| Shortening or advancement of upper eyelid muscle to correct drooping or paralysis | 20 | $10,214 | $511 |
| Complicated repair of wound of eyelids, nose, ears, or lip, 1.1-2.5 cm | 19 | $6,609 | $348 |
| New patient visit (45+ min) | 50 | $6,536 | $131 |
| Reconstruction of eyelid margin | 18 | $6,327 | $352 |
| Insertion of probe into nasal tear duct | 22 | $3,863 | $161 |
| Repair of brow paralysis | 11 | $3,823 | $348 |
| Exam of visual field with intermediate testing | 72 | $3,511 | $48 |
| Short return visit (20+ min) | 42 | $3,066 | $58 |
| Photography of content of eyes | 137 | $2,904 | $21 |
| Established patient problem focused exam of visual system | 26 | $2,499 | $89 |
| Return visit (30+ min) | 30 | $2,431 | $78 |
| Removal of chronic growth of eyelid | 14 | $1,676 | $120 |
| Imaging of retina | 28 | $1,139 | $38 |
| Extended exam of the back part of the eye with retinal drawing | 32 | $821 | $23 |
| Exam of visual field with extended testing | 15 | $744 | $50 |
| Injection into skin growth, 1-7 growths | 14 | $416 | $30 |
2019: 4 services
| Short return visit (20+ min) | 80 | $3,583 | $42 |
| Return visit (30+ min) | 31 | $2,132 | $67 |
| New patient visit (30+ min) | 30 | $1,757 | $59 |
| Probing of nasal tear duct | 13 | $1,743 | $134 |
2018: 2 services
| Return visit (30+ min) | 26 | $1,837 | $71 |
| Short return visit (20+ min) | 18 | $863 | $45 |
Medicaid work
$106,028 in 2024
Medicaid paid $106,028 for 1,835 billed services this clinician did in 2024, up to 67 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 521 | $83,844 |
| Return visit (30+ min) | 354 | $15,219 |
| New patient visit (45+ min) | 99 | $3,943 |
| Short return visit (20+ min) | 530 | $2,215 |
| Short return visit | 319 | $657 |
| INTERMEDIATE VISUAL FIELD XM | 12 | $150 |
| 2024 | 1,835 | 6 | 67 | $106,028 |
| 2023 | 1,780 | 6 | 51 | $89,436 |
| 2022 | 2,432 | 8 | 75 | $86,215 |
| 2021 | 1,860 | 9 | 73 | $74,398 |
| 2020 | 318 | 5 | 38 | $11,061 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 488 | $72,330 |
| Return visit (30+ min) | 293 | $11,815 |
| Short return visit (20+ min) | 788 | $2,640 |
| New patient visit (45+ min) | 85 | $2,327 |
| INTERMEDIATE VISUAL FIELD XM | 25 | $229 |
| Short return visit | 101 | $95 |
2022
| Clinic visit/encounter, all-inclusive | 516 | $74,562 |
| CANTHOPLASTY | 41 | $3,576 |
| Return visit (30+ min) | 334 | $2,640 |
| New patient visit (45+ min) | 159 | $2,335 |
| Blepharoplasty of upper eyelid for excessive skin weighting down lid | 12 | $1,821 |
| Short return visit (20+ min) | 1,319 | $1,177 |
| INTERMEDIATE VISUAL FIELD XM | 39 | $104 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 12 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 469 | $66,697 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 409 | $3,205 |
| CANTHOPLASTY | 12 | $1,404 |
| Return visit (30+ min) | 47 | $893 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 71 | $760 |
| Short return visit (20+ min) | 780 | $606 |
| New patient visit (45+ min) | 34 | $588 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 14 | $185 |
| INTERMEDIATE VISUAL FIELD XM | 24 | $60 |
2020
| Clinic visit/encounter, all-inclusive | 54 | $7,630 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 156 | $3,363 |
| XTRNL OCULAR PHOTOG W/I&R DOCMT MED PROGRESS | 37 | $34 |
| Return visit (30+ min) | 28 | $34 |
| Short return visit (20+ min) | 43 | $0 |
Drugs they prescribed that Part D paid
$133,748
Pharmacies billed $133,748 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 957) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
423 generic and 534 brand-name prescriptions · $133,748 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xiidra | 36 | $34,748 | $965 |
| Miebo | 36 | $26,675 | $741 |
| Restasis | 14 | $9,230 | $659 |
| Alphagan P | 14 | $5,351 | $382 |
| Neomycin-Polymyxin-Dexameth | 477 | $4,021 | $8 |
See all 13 drugs
| Xiidra | 36 | $34,748 | $965 |
| Miebo | 36 | $26,675 | $741 |
| Restasis | 14 | $9,230 | $659 |
| Alphagan P | 14 | $5,351 | $382 |
| Neomycin-Polymyxin-Dexameth | 477 | $4,021 | $8 |
| Tobramycin-Dexamethasone | 58 | $1,811 | $31 |
| Prednisolone Acetate | 62 | $1,741 | $28 |
| Tacrolimus | 15 | $973 | $65 |
| Moxifloxacin | 44 | $857 | $19 |
| Timolol Maleate | 20 | $339 | $17 |
| Azelastine | 16 | $293 | $18 |
| Latanoprost | 28 | $235 | $8 |
| Erythromycin | 19 | $141 | $7 |
Year by year
| 2024 | 957 | 556 | 0% (0) | 56% | $133,748 |
| 2023 | 1,074 | 536 | 0% (0) | 47% | $281,299 |
| 2022 | 1,134 | 604 | 0% (0) | 46% | $1,105,591 |
| 2021 | 1,037 | 493 | None | 38% | $185,488 |
| 2020 | 530 | 261 | 6% (29) | 29% | $21,216 |
| 2019 | 346 | 158 | 12% (41) | 30% | $9,250 |
| 2018 | 273 | 122 | 17% (46) | 23% | $10,137 |
| 2017 | 153 | 71 | 12% (18) | 35% | $8,504 |
| 2016 | 47 | 20 | None | 66% | $4,258 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Xiidra | 40 | $36,670 | $917 |
| Restasis | 23 | $20,711 | $900 |
| Alphagan P | 23 | $10,165 | $442 |
| Neomycin-Polymyxin-Dexameth | 491 | $6,733 | $14 |
| Combigan | 15 | $4,834 | $322 |
| Pred Forte | 11 | $3,814 | $347 |
| Tobramycin-Dexamethasone | 68 | $3,521 | $52 |
| Prednisolone Acetate | 62 | $2,076 | $33 |
| Tacrolimus | 13 | $1,547 | $119 |
| Difluprednate | 12 | $1,292 | $108 |
| Moxifloxacin | 42 | $1,187 | $28 |
| Latanoprost | 42 | $722 | $17 |
| Timolol Maleate | 15 | $669 | $45 |
| Azelastine | 13 | $478 | $37 |
| Dorzolamide-Timolol | 15 | $320 | $21 |
| Amoxicillin-Clavulanate Potass | 23 | $243 | $11 |
| Erythromycin | 28 | $240 | $9 |
| Methylprednisolone | 21 | $190 | $9 |
2022: 16 drugs
| Tepezza | 18 | $1,004,713 | $55,817 |
| Restasis | 16 | $20,199 | $1,262 |
| Xiidra | 17 | $15,451 | $909 |
| Alphagan P | 28 | $8,197 | $293 |
| Neomycin-Polymyxin-Dexameth | 595 | $7,459 | $13 |
| Difluprednate | 31 | $5,067 | $163 |
| Tobradex | 17 | $4,271 | $251 |
| Prednisolone Acetate | 45 | $2,508 | $56 |
| Tobramycin-Dexamethasone | 24 | $1,615 | $67 |
| Moxifloxacin | 34 | $1,482 | $44 |
| Azelastine | 13 | $833 | $64 |
| Dorzolamide | 15 | $671 | $45 |
| Latanoprost | 35 | $534 | $15 |
| Dorzolamide-Timolol | 23 | $410 | $18 |
| Erythromycin | 50 | $403 | $8 |
| Methylprednisolone | 22 | $194 | $9 |
2021: 13 drugs
| Restasis | 14 | $18,916 | $1,351 |
| Neomycin-Polymyxin-Dexameth | 507 | $6,970 | $14 |
| Moxifloxacin | 64 | $2,625 | $41 |
| Durezol | 11 | $2,361 | $215 |
| Olopatadine | 20 | $2,234 | $112 |
| Erythromycin | 131 | $1,612 | $12 |
| Prednisolone Acetate | 24 | $1,296 | $54 |
| Latanoprost | 19 | $353 | $19 |
| Ofloxacin | 20 | $239 | $12 |
| Desonide | 11 | $199 | $18 |
| Cephalexin | 22 | $160 | $7 |
| Amoxicillin-Clavulanate Potass | 17 | $142 | $8 |
| Methylprednisolone | 22 | $140 | $6 |
2020: 10 drugs
| Neomycin-Polymyxin-Dexameth | 208 | $3,274 | $16 |
| Tobradex | 12 | $2,819 | $235 |
| Olopatadine | 22 | $1,520 | $69 |
| Moxifloxacin | 24 | $1,294 | $54 |
| Prednisolone Acetate | 13 | $955 | $73 |
| Erythromycin | 56 | $641 | $11 |
| Cephalexin | 43 | $341 | $8 |
| Methylprednisolone | 26 | $266 | $10 |
| Hydrocodone-Acetaminophen | 21 | $114 | $5 |
| Ondansetron | 14 | $101 | $7 |
2019: 7 drugs
| Tobradex | 15 | $3,473 | $232 |
| Neomycin-Polymyxin-Dexameth | 127 | $2,096 | $17 |
| Methylprednisolone | 17 | $275 | $16 |
| Cephalexin | 35 | $267 | $8 |
| Erythromycin | 23 | $251 | $11 |
| Ondansetron | 22 | $136 | $6 |
| Acetaminophen-Codeine | 29 | $134 | $5 |
2018: 7 drugs
| Neomycin-Polymyxin-Dexameth | 67 | $987 | $15 |
| Erythromycin | 39 | $412 | $11 |
| Ondansetron | 16 | $219 | $14 |
| Methylprednisolone | 16 | $196 | $12 |
| Hydrocodone-Acetaminophen | 30 | $160 | $5 |
| Cephalexin | 18 | $98 | $5 |
| Acetaminophen-Codeine | 11 | $37 | $3 |
2017: 5 drugs
| Prednisolone Acetate | 18 | $1,073 | $60 |
| Erythromycin | 27 | $293 | $11 |
| Ofloxacin | 13 | $257 | $20 |
| Neomycin-Polymyxin-Dexameth | 11 | $165 | $15 |
| Hydrocodone-Acetaminophen | 17 | $53 | $3 |
2016: 1 drug
| Prednisolone Acetate | 11 | $503 | $46 |
Money from drug and device companies
$32,987 in 2025
| 2025 | 8 | 82 | $28,750 | $32,987 |
| 2024 | 11 | 89 | $45,250 | $48,961 |
| 2023 | 11 | 114 | $53,375 | $59,360 |
| 2022 | 13 | 71 | $24,400 | $29,008 |
| 2021 | 7 | 24 | $2,118 | $2,764 |
| 2020 | 7 | 11 | None | $253 |
| 2019 | 7 | 7 | None | $593 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Tepezza | $32,139 | 39 payments
|
| Abbvie | Durysta | $506 | 20 payments
|
| Bausch & Lomb Americas | Miebo | $145 | 15 payments
|
| Alcon Vision | Rocklatan | $76 | 3 payments
|
| Harrow Eye | Vevye | $52 | 2 payments
|
| Apellis Pharmaceuticals | Syfovre | $29 | 1 payment
|
See all 82 published payments
| Amgen | Travel · 2025-12-31 | Tepezza | $140 |
| Amgen | Meals · 2025-12-31 | Tepezza | $129 |
| Amgen | Paid to speak or teach · 2025-12-18 | Tepezza | $3,000 |
| Amgen | Paid to speak or teach · 2025-12-18 | Tepezza | $1,000 |
| Amgen | Meals · 2025-12-16 | Tepezza | $16 |
| Amgen | Travel · 2025-12-12 | Tepezza | $425 |
| Oyster Point Pharma | Meals · 2025-12-12 | Tyrvaya | $17 |
| Amgen | Meals · 2025-12-11 | Tepezza | $26 |
| Amgen | Meals · 2025-12-05 | Tepezza | $100 |
| Amgen | Travel · 2025-12-04 | Tepezza | $264 |
| Amgen | Travel · 2025-12-04 | Tepezza | $1,086 |
| Amgen | Meals · 2025-12-04 | Tepezza | $62 |
| Bausch & Lomb Americas | Meals · 2025-12-04 | Miebo | $5 |
| Amgen | Meals · 2025-12-03 | Tepezza | $21 |
| Bausch & Lomb Americas | Meals · 2025-11-26 | Miebo | $10 |
| Bausch & Lomb Americas | Meals · 2025-11-21 | Miebo | $9 |
| Abbvie | Meals · 2025-11-06 | Durysta | $26 |
| Amgen | Meals · 2025-10-28 | Tepezza | $18 |
| Amgen | Meals · 2025-10-21 | Tepezza | $25 |
| Abbvie | Meals · 2025-10-10 | Durysta | $24 |
| Bausch & Lomb Americas | Meals · 2025-10-05 | Miebo | $11 |
| Amgen | Meals · 2025-09-25 | Tepezza | $27 |
| Amgen | Meals · 2025-09-23 | Tepezza | $14 |
| Abbvie | Meals · 2025-09-18 | Durysta | $31 |
| Abbvie | Meals · 2025-09-12 | Durysta | $33 |
| Alcon Vision | Meals · 2025-09-11 | Tryptyr | $18 |
| Amgen | Meals · 2025-09-10 | Tepezza | $28 |
| Abbvie | Meals · 2025-09-04 | Lumigan | $20 |
| Abbvie | Meals · 2025-08-28 | Durysta | $28 |
| Amgen | Meals · 2025-08-28 | Tepezza | $23 |
| Apellis Pharmaceuticals | Meals · 2025-08-25 | Syfovre | $29 |
| Amgen | Paid to speak or teach · 2025-08-20 | Tepezza | $2,500 |
| Amgen | Meals · 2025-08-18 | Tepezza | $24 |
| Amgen | Paid to speak or teach · 2025-08-15 | Tepezza | $2,500 |
| Abbvie | Meals · 2025-08-14 | Durysta | $33 |
| Bausch & Lomb Americas | Meals · 2025-07-29 | Xiidra | $25 |
| Abbvie | Meals · 2025-07-24 | Lumigan | $28 |
| Amgen | Paid to speak or teach · 2025-07-23 | Tepezza | $2,500 |
| Amgen | Meals · 2025-07-21 | Tepezza | $35 |
| Alcon Vision | Meals · 2025-07-14 | Eysuvis | $24 |
| Abbvie | Meals · 2025-07-03 | Durysta | $30 |
| Tarsus Pharmaceuticals | Meals · 2025-06-23 | Xdemvy | $24 |
| Bausch & Lomb Americas | Meals · 2025-06-23 | Miebo | $8 |
| Bausch & Lomb Americas | Meals · 2025-06-23 | Miebo | $4 |
| Bausch & Lomb Americas | Meals · 2025-06-23 | Miebo | $8 |
| Bausch & Lomb Americas | Meals · 2025-06-23 | Miebo | $8 |
| Amgen | Meals · 2025-06-19 | Tepezza | $33 |
| Amgen | Paid to speak or teach · 2025-06-18 | Tepezza | $2,500 |
| Amgen | Meals · 2025-06-13 | Tepezza | $15 |
| Amgen | Meals · 2025-06-06 | Tepezza | $29 |
| Harrow Eye | Meals · 2025-05-29 | Vevye | $25 |
| Amgen | Paid to speak or teach · 2025-05-27 | Tepezza | $2,500 |
| Amgen | Paid to speak or teach · 2025-05-27 | Tepezza | $2,500 |
| Abbvie | Meals · 2025-05-22 | Lumigan | $7 |
| Abbvie | Meals · 2025-05-20 | Lumigan | $26 |
| Abbvie | Meals · 2025-05-15 | Durysta | $25 |
| Bausch & Lomb Americas | Meals · 2025-05-14 | Miebo | $7 |
| Bausch & Lomb Americas | Meals · 2025-05-14 | Miebo | $7 |
| Alcon Vision | Meals · 2025-05-08 | Rocklatan | $34 |
| Harrow Eye | Meals · 2025-04-28 | Vevye | $27 |
| Abbvie | Meals · 2025-04-26 | Lumigan | $8 |
| Bausch & Lomb Americas | Meals · 2025-04-23 | Miebo | $5 |
| Bausch & Lomb Americas | Meals · 2025-04-23 | Xiidra | $6 |
| Abbvie | Meals · 2025-04-17 | Durysta | $29 |
| Bausch & Lomb Americas | Meals · 2025-04-14 | Miebo | $19 |
| Abbvie | Meals · 2025-04-03 | Durysta | $32 |
| Amgen | Paid to speak or teach · 2025-04-03 | Tepezza | $1,250 |
| Amgen | Meals · 2025-04-01 | Tepezza | $29 |
| Bausch & Lomb Americas | Meals · 2025-03-31 | Xiidra | $13 |
| Amgen | Paid to speak or teach · 2025-03-28 | Tepezza | $2,500 |
| Abbvie | Meals · 2025-03-20 | Durysta | $32 |
| Abbvie | Meals · 2025-03-13 | Durysta | $29 |
| Amgen | Paid to speak or teach · 2025-03-07 | Tepezza | $3,000 |
| Amgen | Paid to speak or teach · 2025-03-07 | Tepezza | $500 |
| Amgen | Meals · 2025-03-07 | Tepezza | $21 |
| Amgen | Travel · 2025-02-27 | Tepezza | $649 |
| Amgen | Meals · 2025-02-26 | Tepezza | $122 |
| Abbvie | Meals · 2025-02-24 | Durysta | $29 |
| Abbvie | Meals · 2025-02-20 | Lumigan | $15 |
| Amgen | Paid to speak or teach · 2025-02-04 | Tepezza | $2,500 |
| Amgen | Meals · 2025-01-28 | Tepezza | $27 |
| Abbvie | Meals · 2025-01-23 | Durysta | $21 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $48,961
| Amgen | Tepezza | $47,760 | 47 payments
|
| Abbvie | Durysta | $603 | 22 payments
|
| Astellas Pharma US | Izervay | $231 | 7 payments
|
| Apellis Pharmaceuticals | Syfovre | $150 | 2 payments
|
| Alcon Vision | Rocklatan | $79 | 4 payments
|
| Bausch & Lomb Americas | Miebo | $39 | 2 payments
|
| Dompe US | Oxervate | $23 | 1 payment
|
| Oyster Point Pharma | Tyrvaya | $20 | 1 payment
|
| Sight Sciences | Omni Surgical System | $20 | 1 payment
|
| Genentech USA | Vabysmo | $19 | 1 payment
|
| Tarsus Pharmaceuticals | Xdemvy | $16 | 1 payment
|
2023: $59,360
| Horizon Therapeutics plc | Tepezza | $58,339 | 67 payments
|
| AbbVie | Durysta | $492 | 16 payments
|
| Alcon Vision | Rocklatan | $180 | 16 payments
|
| Biotissue Holdings | Prokera | $70 | 3 payments
|
| Oyster Point Pharma | Tyrvaya | $68 | 3 payments
|
| Johnson & Johnson Surgical Vision | Lipiflow System Activator (Disposable) | $63 | 3 payments
|
| Bausch & Lomb Americas | Vyzulta | $39 | 2 payments
|
| Astellas Pharma US | None | $35 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $29 | 1 payment
|
| Merz North America | Xeomin | $26 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $19 | 1 payment
|
2022: $29,008
| Horizon Therapeutics plc | Tepezza | $27,163 | 45 payments
|
| Carl Zeiss Meditec USA | Clarus | $912 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $328 | 9 payments
|
| Kala Pharmaceuticals | Inveltys | $150 | 1 payment
|
| Oyster Point Pharma | Tyrvaya | $131 | 1 payment
|
| Abbvie | Durysta | $99 | 4 payments
|
| Alcon Vision | Rocklatan | $62 | 3 payments
|
| BioTissue Holdings | Prokera | $55 | 2 payments
|
| Sun Pharmaceutical Industries | Cequa | $25 | 1 payment
|
| Allergan | None | $23 | 1 payment
|
| Apellis Pharmaceuticals | None | $22 | 1 payment
|
| Bausch & Lomb Americas | Xipere | $20 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $17 | 1 payment
|
2021: $2,764
| Horizon Therapeutics plc | Tepezza | $1,879 | 4 payments
|
| Allergan | Vuity | $479 | 3 payments
|
| Novartis Pharmaceuticals | Xiidra | $219 | 8 payments
|
| Aerie Pharmaceuticals | Rhopressa | $94 | 5 payments
|
| Tissuetech | Prokera | $44 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Prolensa | $35 | 2 payments
|
| Sight Sciences | Tearcare Smartlid | $15 | 1 payment
|
2020: $253
| Novartis Pharmaceuticals | Xiidra | $61 | 4 payments
|
| Horizon Therapeutics plc | Tepezza | $45 | 2 payments
|
| Allergan | Lumigan | $38 | 1 payment
|
| Merz North America | Xeomin | $34 | 1 payment
|
| Axogen | Avance Nerve Graft | $27 | 1 payment
|
| Stryker | Oculoplastic | $25 | 1 payment
|
| Aerie Pharmaceuticals | Rocklatan | $22 | 1 payment
|
2019: $593
| Mallinckrodt Enterprises | Acthar | $120 | 1 payment
|
| Aerie Pharmaceuticals | Rhopressa | $117 | 1 payment
|
| Allergan | Botox Cosmetic | $110 | 1 payment
|
| Galderma Laboratories L.P. | None | $108 | 1 payment
|
| Stryker | Universal Upper-Face | $81 | 1 payment
|
| Axogen | Axoguard Nerve Protector | $30 | 1 payment
|
| Dompe US | Oxervate | $27 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 0.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1609296466
- Licence
- CA A137508California A137508: Current · expires 2027-03-31
- Trained
- Perelman School of Med at the University of Pennsylvania, 2014
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 2452 Watson Ct, Palo Alto, CA, 94303
- NPI first listed
- 2014-04-21
- NPI last updated
- 2018-07-20
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 751 S Bascom Ave, San Jose, CA, 95128